131 related articles for article (PubMed ID: 24050112)
1. New serotonin 5-HT1A receptor agonists endowed with antinociceptive activity in vivo.
Valhondo M; Marco I; Martín-Fontecha M; Vázquez-Villa H; Ramos JA; Berkels R; Lauterbach T; Benhamú B; López-Rodríguez ML
J Med Chem; 2013 Oct; 56(20):7851-61. PubMed ID: 24050112
[TBL] [Abstract][Full Text] [Related]
2. Synthesis and structure-activity relationship studies in serotonin 5-HT(1A) receptor agonists based on fused pyrrolidone scaffolds.
Cappelli A; Manini M; Valenti S; Castriconi F; Giuliani G; Anzini M; Brogi S; Butini S; Gemma S; Campiani G; Giorgi G; Mennuni L; Lanza M; Giordani A; Caselli G; Letari O; Makovec F
Eur J Med Chem; 2013 May; 63():85-94. PubMed ID: 23466604
[TBL] [Abstract][Full Text] [Related]
3. Synthesis, biological evaluation and molecular modeling of 1-oxa-4-thiaspiro- and 1,4-dithiaspiro[4.5]decane derivatives as potent and selective 5-HT
Franchini S; Manasieva LI; Sorbi C; Battisti UM; Fossa P; Cichero E; Denora N; Iacobazzi RM; Cilia A; Pirona L; Ronsisvalle S; Aricò G; Brasili L
Eur J Med Chem; 2017 Jan; 125():435-452. PubMed ID: 27689727
[TBL] [Abstract][Full Text] [Related]
4. New dual 5-HT1A and 5-HT7 receptor ligands derived from SYA16263.
Ofori E; Onyameh EK; Gonela UM; Voshavar C; Bricker B; Swanson TL; Eshleman AJ; Schmachtenberg JL; Bloom SH; Janowsky AJ; Ablordeppey SY
Eur J Med Chem; 2021 Mar; 214():113243. PubMed ID: 33582388
[TBL] [Abstract][Full Text] [Related]
5. New serotonin 5-HT(1A) receptor agonists with neuroprotective effect against ischemic cell damage.
Marco I; Valhondo M; Martín-Fontecha M; Vázquez-Villa H; Del Río J; Planas A; Sagredo O; Ramos JA; Torrecillas IR; Pardo L; Frechilla D; Benhamú B; López-Rodríguez ML
J Med Chem; 2011 Dec; 54(23):7986-99. PubMed ID: 22029386
[TBL] [Abstract][Full Text] [Related]
6. Discovery of a novel 5-HT(3) antagonist/5-HT(1A) agonist 3-amino-5,6,7,8-tetrahydro-2-{4-[4-(quinolin-2-yl)piperazin-1-yl]butyl}quinazolin-4(3H)-one (TZB-30878) as an orally bioavailable agent for irritable bowel syndrome.
Asagarasu A; Matsui T; Hayashi H; Tamaoki S; Yamauchi Y; Minato K; Sato M
J Med Chem; 2010 Nov; 53(21):7549-63. PubMed ID: 20931963
[TBL] [Abstract][Full Text] [Related]
7. Novel derivatives of 2-pyridinemethylamine as selective, potent, and orally active agonists at 5-HT1A receptors.
Vacher B; Bonnaud B; Funes P; Jubault N; Koek W; Assié MB; Cosi C; Kleven M
J Med Chem; 1999 May; 42(9):1648-60. PubMed ID: 10229633
[TBL] [Abstract][Full Text] [Related]
8. Synthesis, biological evaluation, and docking studies of tetrahydrofuran- cyclopentanone- and cyclopentanol-based ligands acting at adrenergic α₁- and serotonine 5-HT1A receptors.
Prandi A; Franchini S; Manasieva LI; Fossa P; Cichero E; Marucci G; Buccioni M; Cilia A; Pirona L; Brasili L
J Med Chem; 2012 Jan; 55(1):23-36. PubMed ID: 22145629
[TBL] [Abstract][Full Text] [Related]
9. Antinociceptive, antiallodynic and antihyperalgesic effects of the 5-HT
Sałat K; Kołaczkowski M; Furgała A; Rojek A; Śniecikowska J; Varney MA; Newman-Tancredi A
Neuropharmacology; 2017 Oct; 125():181-188. PubMed ID: 28751195
[TBL] [Abstract][Full Text] [Related]
10. Pharmacological, neurochemical, and behavioral profile of JB-788, a new 5-HT1A agonist.
Picard M; Morisset S; Cloix JF; Bizot JC; Guerin M; Beneteau V; Guillaumet G; Hevor TK
Neuroscience; 2010 Sep; 169(3):1337-46. PubMed ID: 20580787
[TBL] [Abstract][Full Text] [Related]
11. Synthesis and evaluation of arylpiperazines derivatives of 3,5-dioxo-(2H,4H)-1,2,4-triazine as 5-HT1AR ligands.
Kumar JSD; Majo VJ; Prabhakaran J; Mann JJ
Bioorg Med Chem Lett; 2014 Oct; 24(19):4759-4762. PubMed ID: 25182564
[TBL] [Abstract][Full Text] [Related]
12. Synthesis, 5-HT1A and 5-HT2A receptor activity of new 1-phenylpiperazinylpropyl derivatives with arylalkyl substituents in position 7 of purine-2,6-dione.
Chloń G; Pawłowski M; Duszyńska B; Szaro A; Tatarczńska E; Kłodzińska AL; Chojnacka-Wójcik E
Pol J Pharmacol; 2001; 53(4):359-68. PubMed ID: 11990082
[TBL] [Abstract][Full Text] [Related]
13. Allosteric modulation of 5-HT(1A) receptors by zinc: Binding studies.
Barrondo S; Sallés J
Neuropharmacology; 2009 Feb; 56(2):455-62. PubMed ID: 18951909
[TBL] [Abstract][Full Text] [Related]
14. Anxiolytic-like effect of a serotonergic ligand with high affinity for 5-HT1A, 5-HT2A and 5-HT3 receptors.
Delgado M; Caicoya AG; Greciano V; Benhamú B; López-Rodríguez ML; Fernández-Alfonso MS; Pozo MA; Manzanares J; Fuentes JA
Eur J Pharmacol; 2005 Mar; 511(1):9-19. PubMed ID: 15777774
[TBL] [Abstract][Full Text] [Related]
15. 1,3-Dioxane as a scaffold for potent and selective 5-HT
Franchini S; Sorbi C; Linciano P; Carnevale G; Tait A; Ronsisvalle S; Buccioni M; Del Bello F; Cilia A; Pirona L; Denora N; Iacobazzi RM; Brasili L
Eur J Med Chem; 2019 Aug; 176():310-325. PubMed ID: 31112892
[TBL] [Abstract][Full Text] [Related]
16. New pyridobenzoxazepine derivatives derived from 5-(4-methylpiperazin-1-yl)-8-chloro-pyrido[2,3-b][1,5]benzoxazepine (JL13): chemical synthesis and pharmacological evaluation.
Liégeois JF; Deville M; Dilly S; Lamy C; Mangin F; Résimont M; Tarazi FI
J Med Chem; 2012 Feb; 55(4):1572-82. PubMed ID: 22268448
[TBL] [Abstract][Full Text] [Related]
17. In vitro characterization of SLV308 (7-[4-methyl-1-piperazinyl]-2(3H)-benzoxazolone, monohydrochloride): a novel partial dopamine D2 and D3 receptor agonist and serotonin 5-HT1A receptor agonist.
Glennon JC; Van Scharrenburg G; Ronken E; Hesselink MB; Reinders JH; Van Der Neut M; Long SK; Feenstra RW; McCreary AC
Synapse; 2006 Dec; 60(8):599-608. PubMed ID: 17001660
[TBL] [Abstract][Full Text] [Related]
18. In vitro profile of the antidepressant candidate OPC-14523 at rat and human 5-HT1A receptors.
Jordan S; Chen R; Koprivica V; Hamilton R; Whitehead RE; Tottori K; Kikuchi T
Eur J Pharmacol; 2005 Jul; 517(3):165-73. PubMed ID: 15985260
[TBL] [Abstract][Full Text] [Related]
19. New 4-[omega-(diarylmethylamino)alkyl]- and 4-[omega-(diarylmethoxy)alkyl]-1-arylpiperazines as selective 5-HT1A/5-HT2A receptor ligands with differentiated in vivo activity.
Paluchowska MH; Charakchieva-Minol S; Tatarczyńska E; Kłodzińska A; Stachowicz K; Chojnacka-Wójcik E
Pol J Pharmacol; 2004; 56(6):743-54. PubMed ID: 15662087
[TBL] [Abstract][Full Text] [Related]
20. KKHA-761, a potent D3 receptor antagonist with high 5-HT1A receptor affinity, exhibits antipsychotic properties in animal models of schizophrenia.
Park WK; Jeong D; Cho H; Lee SJ; Cha MY; Pae AN; Choi KI; Koh HY; Kong JY
Pharmacol Biochem Behav; 2005 Oct; 82(2):361-72. PubMed ID: 16216322
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
